Literature DB >> 9755718

Enzymology of tirapazamine metabolism: a review.

A V Patterson1, M P Saunders, E C Chinje, L H Patterson, I J Stratford.   

Abstract

The enzymology of triapazamine (TPZ, SR 4233, WIN 59075, 3-amino-1,2,4-benzotriazene 1,4-dioxide, Tirazone) has been extensively studied in rodents and to a lesser extent in human systems. While it is clear that the initial reductive step in TPZ activation is enzyme-mediated, there is limited consensus in the published literature as to the relative contributions of the cellular reductases involved. Moreover, not only is the importance of subcellular localization for these putative activating reductase(s) far from clear, but their activity profiles in vivo are poorly defined. The same might also be said of the potential detoxifying enzymes. This review will attempt to establish what common ground exists regarding the enzymology of TPZ metabolism, and will relate the available evidence to the enzyme profiles found in human cell lines in vitro, as well as in xenograft models and human solid tumours.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755718

Source DB:  PubMed          Journal:  Anticancer Drug Des        ISSN: 0266-9536


  15 in total

1.  DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide.

Authors:  Venkatraman Junnotula; Anuruddha Rajapakse; Leire Arbillaga; Adela López de Cerain; Beatriz Solano; Raquel Villar; Antonio Monge; Kent S Gates
Journal:  Bioorg Med Chem       Date:  2010-03-19       Impact factor: 3.641

2.  Tricyclic [1,2,4]triazine 1,4-dioxides as hypoxia selective cytotoxins.

Authors:  Michael P Hay; Kevin O Hicks; Karin Pchalek; Ho H Lee; Adrian Blaser; Frederik B Pruijn; Robert F Anderson; Sujata S Shinde; William R Wilson; William A Denny
Journal:  J Med Chem       Date:  2008-10-11       Impact factor: 7.446

Review 3.  Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents.

Authors:  A M Mfuh; O V Larionov
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

4.  Isotopic labeling experiments that elucidate the mechanism of DNA strand cleavage by the hypoxia-selective antitumor agent 1,2,4-benzotriazine 1,4-di-N-oxide.

Authors:  Xiulong Shen; Anuruddha Rajapakse; Fabio Gallazzi; Venkatraman Junnotula; Tarra Fuchs-Knotts; Rainer Glaser; Kent S Gates
Journal:  Chem Res Toxicol       Date:  2013-12-19       Impact factor: 3.739

5.  Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting.

Authors:  Yvette M Delahoussaye; Michael P Hay; Frederik B Pruijn; William A Denny; J Martin Brown
Journal:  Biochem Pharmacol       Date:  2003-06-01       Impact factor: 5.858

6.  DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2).

Authors:  Goutam Chowdhury; Venkatraman Junnotula; J Scott Daniels; Marc M Greenberg; Kent S Gates
Journal:  J Am Chem Soc       Date:  2007-09-27       Impact factor: 15.419

7.  Initiation of DNA strand cleavage by 1,2,4-benzotriazine 1,4-dioxide antitumor agents: mechanistic insight from studies of 3-methyl-1,2,4-benzotriazine 1,4-dioxide.

Authors:  Venkatraman Junnotula; Ujjal Sarkar; Sarmistha Sinha; Kent S Gates
Journal:  J Am Chem Soc       Date:  2009-01-28       Impact factor: 15.419

8.  Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

Authors:  E C Chinje; A V Patterson; M P Saunders; S D Lockyer; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

9.  Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.

Authors:  L H Patterson; S R McKeown; K Ruparelia; J A Double; M C Bibby; S Cole; I J Stratford
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

10.  NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line.

Authors:  M P Saunders; A V Patterson; E C Chinje; A L Harris; I J Stratford
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.